학술논문
532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S790-S791
Subject
Language
ISSN
0923-7534